← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV17행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
FT538 (FT538)
Fate Therapeutics·Acute Myeloid Leukemia
5 trials
Overview
Program
FT538
Overview
Company
Fate Therapeutics
Overview
Modality
CGT
Overview
Target
Acute Myeloid Leukemia
Overview
Indication
Acute Myeloid Leukemia; AML, Adult
Overview
Phase
PHASE_1
Overview
Status
DISCONTINUED
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
FT538, iPSC-derived NK cells, enhance AML cell killing when combined with chemotherapy.. Induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells offer an opportunity for a standardized, off-the-shelf treatment with the potential to treat a wider population of acute myeloid leukaemia (AML) patients than the current standard of care. FT538 iPSC-NKs express a high-affinity, noncleavabl…
Clinical
Safety signal
FT538, iPSC-derived NK cells, enhance AML cell killing when combined with chemotherapy.. Induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells offer an opportunity for a standardized, off-the-shelf treatment with the potential to treat a wider population of acute myeloid leukaemia (AML) patients than the current standard of care. FT538 iPSC-NKs express a high-affinity, noncleavabl…
Clinical
Reported ORR
0%
Clinical
Result source
ClinicalTrials.gov NCT04714372
Clinical
Program phase
PHASE_1
Clinical
Trial ref
NCT04714372